WO2004037183A3 - Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases - Google Patents

Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases Download PDF

Info

Publication number
WO2004037183A3
WO2004037183A3 PCT/US2003/033400 US0333400W WO2004037183A3 WO 2004037183 A3 WO2004037183 A3 WO 2004037183A3 US 0333400 W US0333400 W US 0333400W WO 2004037183 A3 WO2004037183 A3 WO 2004037183A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
disease
pkg
compound
arteriosclerosis
Prior art date
Application number
PCT/US2003/033400
Other languages
French (fr)
Other versions
WO2004037183A2 (en
Inventor
Nestor F Gonzalez-Cadavid
Jacob Rajfer
Original Assignee
Harbor Ucla Res & Education
Nestor F Gonzalez-Cadavid
Jacob Rajfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Ucla Res & Education, Nestor F Gonzalez-Cadavid, Jacob Rajfer filed Critical Harbor Ucla Res & Education
Priority to AU2003286555A priority Critical patent/AU2003286555A1/en
Priority to US10/779,069 priority patent/US8133903B2/en
Publication of WO2004037183A2 publication Critical patent/WO2004037183A2/en
Publication of WO2004037183A3 publication Critical patent/WO2004037183A3/en
Priority to US13/372,094 priority patent/US20120141454A1/en
Priority to US14/215,444 priority patent/US20140200219A1/en
Priority to US15/277,550 priority patent/US20170239257A1/en
Priority to US15/832,918 priority patent/US20180318307A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation,general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, PDE-5 inhibitor, a compound that elevates cGMP and/or PKG, a stimulator of guanylyl cyclase and/or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity. In certain embodiments, the composition may be a gene therapy vector.
PCT/US2003/033400 2002-10-22 2003-10-21 Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases WO2004037183A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003286555A AU2003286555A1 (en) 2002-10-22 2003-10-21 Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
US10/779,069 US8133903B2 (en) 2003-10-21 2004-02-13 Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US13/372,094 US20120141454A1 (en) 2003-10-21 2012-02-13 Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases
US14/215,444 US20140200219A1 (en) 2002-10-22 2014-03-17 Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases
US15/277,550 US20170239257A1 (en) 2002-10-22 2016-09-27 Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases
US15/832,918 US20180318307A1 (en) 2003-10-21 2017-12-06 Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42028102P 2002-10-22 2002-10-22
US60/420,281 2002-10-22

Publications (2)

Publication Number Publication Date
WO2004037183A2 WO2004037183A2 (en) 2004-05-06
WO2004037183A3 true WO2004037183A3 (en) 2004-08-05

Family

ID=32176545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033400 WO2004037183A2 (en) 2002-10-22 2003-10-21 Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases

Country Status (2)

Country Link
AU (1) AU2003286555A1 (en)
WO (1) WO2004037183A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004038328A1 (en) * 2004-08-06 2006-03-16 Bayer Healthcare Ag New uses of 2-phenyl-substituted imidazotriazinone derivatives
CN101106997A (en) 2004-08-17 2008-01-16 约翰·霍普金斯大学 PDE5 inhibitor compositions and methods for treating cardiac indications
TWI339578B (en) 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
RU2369392C2 (en) * 2005-06-10 2009-10-10 Донг-А Фармасьютикал. Ко., Лтд. Pyrazolpyramidinon derivative-containing medicine for liver diseases treatment and prevention
CA2704100C (en) 2007-10-26 2017-07-04 Pacific Therapeutics Ltd. Compositions and methods for treating fibroproliferative disorders
MX350145B (en) 2011-07-20 2017-08-28 Mediwound Ltd Proteolytic extract from bromelain for the treatment of connective tissue disorders.
US9789126B2 (en) 2012-12-21 2017-10-17 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
MX2017008931A (en) * 2015-01-06 2017-10-19 Imprimis Pharmaceuticals Inc Pharmaceutical formulations of xanthine or xanthine derivatives.
EP3595623A1 (en) 2017-03-14 2020-01-22 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
US11033549B2 (en) 2017-03-14 2021-06-15 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
CN112773898A (en) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 Application of phosphodiesterase 5 inhibitor in preparing anti-fibrosis disease medicine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5981563A (en) * 1995-04-28 1999-11-09 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5990103A (en) * 1994-08-25 1999-11-23 Hoechst Aktiengesllschaft Combination preparation for use in immunological diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990103A (en) * 1994-08-25 1999-11-23 Hoechst Aktiengesllschaft Combination preparation for use in immunological diseases
US5981563A (en) * 1995-04-28 1999-11-09 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders

Also Published As

Publication number Publication date
AU2003286555A8 (en) 2004-05-13
AU2003286555A1 (en) 2004-05-13
WO2004037183A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
Weiss et al. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome
WO2004037183A3 (en) Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
Stacy Smith et al. Short incubation PDT versus 5-FU in treating actinic keratoses
IL159205A0 (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
WO2005051229A3 (en) Devices delivering therapeutic agents and methods regarding the same
Wang et al. Treatment of skin cancer and pre-cancer using topical ALA-PDT—a single hospital experience
WO2002002090A3 (en) Inhibitors of copper-containing amine oxidases
WO2003020202A3 (en) Method for reducing hypertension and heart failure
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
DE60107065D1 (en) TREATMENT OF CONGESTIVE HEART FAILURE BY PRE-TREATED AUTOLOGOUS BLOOD
Green et al. Claviculectomy for subclavian venous repair: long-term functional results
WO2003009777A3 (en) Delivery of therapeutic capable agents
Schanzer Endovenous ablation plus microphlebectomy/sclerotherapy for the treatment of varicose veins: single or two-stage procedure?
Moore et al. Minocycline-induced postsclerotherapy pigmentation successfully treated with a picosecond alexandrite laser
Russell et al. Zimmer splintage: a simple effective treatment for keloids following ear-piercing
WO2001089517A3 (en) Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors
WO2001035997A3 (en) Use of low-dose pdt to inhibit restenosis
WO1999040945A3 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
Mazzali et al. An elevated serum uric acid (UA) causes kidney damage: evidence for a novel crystal independent mechanism
Hansen et al. Piercing of the glans penis
CA3168207A1 (en) Cellular uptake
Purcell et al. Intense pulsed light therapy in the management of hereditary benign telangiectasia
Takemaru et al. Labial adhesions causing recurrent urinary-tract infections in an elderly woman
Edris et al. Vaginal tightening surgery: a new technique
RU2796245C1 (en) Method of treatment of skin neoplasms by cryodestruction in animals, mainly in cats and dogs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP